L04AA10 • sirolimus • Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants
Sirolimus, also known as rapamycin, is an immunosuppressive agent primarily used to prevent organ rejection following renal transplantation. It works by inhibiting the mTOR (mammalian target of rapamycin) pathway, reducing T and B lymphocyte proliferation and suppressing the immune response.
Sirolimus is administered orally, usually once daily, and is used in combination with other immunosuppressive medications such as cyclosporine and corticosteroids. It is indicated for patients requiring prevention of acute organ rejection or those who cannot tolerate other immunosuppressive therapies.
Common side effects include hyperlipidemia, hypertension, anemia, thrombocytopenia, and infections. In rare cases, severe adverse reactions such as interstitial pneumonitis or renal function impairment may occur. Regular monitoring of hematological and metabolic parameters is essential during treatment.
Sirolimus is an effective therapeutic option for patients undergoing organ transplantation, contributing to prolonged graft survival and reduced risk of rejection.
Substance: sirolimus
Date of last drug list: 01-07-2015
Commercial code: W61480002
Concentration: 2mg
Pharmaceutical form: dragees
Quantity: 100
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).